US Markets

Xeris Pharma's low blood sugar treatment wins FDA approval

The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc's glucagon pen that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday.

Sept 10 (Reuters) - The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc's XERS.O glucagon pen that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday.

The condition, called hypoglycemia, can cause acute cognitive impairment. It can occur multiple times a month, can also result in heart disease, seizure and coma in its severe form.

Gvoke, Xeris' glucagon pen is an pre-filled device with liquid stable form of glucagon.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shailesh Kuber)

((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Reuters Messaging: Aakash.B.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More